409 related articles for article (PubMed ID: 34709601)
1. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
2. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
3. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
Xu H; Cai R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
[No Abstract] [Full Text] [Related]
4. Avatrombopag for the treatment of immune thrombocytopenia.
Długosz-Danecka M; Zdziarska J; Jurczak W
Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of avatrombopag for the treatment of thrombocytopenia.
Virk ZM; Kuter DJ; Al-Samkari H
Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
[No Abstract] [Full Text] [Related]
6. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia.
Jain S; Gernsheimer T; Kolodny S; Bernheisel C; Vredenburg M; Panch SR
Platelets; 2023 Dec; 34(1):2195016. PubMed ID: 37013676
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
[TBL] [Abstract][Full Text] [Related]
8. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
9. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
10. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
[No Abstract] [Full Text] [Related]
11. Avatrombopag: First Global Approval.
Shirley M
Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
[TBL] [Abstract][Full Text] [Related]
12. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
[TBL] [Abstract][Full Text] [Related]
14. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
Bussel JB; Kuter DJ; Aledort LM; Kessler CM; Cuker A; Pendergrass KB; Tang S; McIntosh J
Blood; 2014 Jun; 123(25):3887-94. PubMed ID: 24802775
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.
Al-Samkari H; Nagalla S
Platelets; 2022 Feb; 33(2):257-264. PubMed ID: 33586606
[TBL] [Abstract][Full Text] [Related]
17. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Kuter DJ
Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
[TBL] [Abstract][Full Text] [Related]
18. Avatrombopag for adults with early versus chronic immune thrombocytopenia.
Virk ZM; Leaf RK; Kuter DJ; Goodarzi K; Connell NT; Connors JM; Al-Samkari H
Am J Hematol; 2024 Feb; 99(2):155-162. PubMed ID: 38063420
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
